Glucagon-like peptide-1 treatment reduces the risk of diabetes-type 2 related amputations: A cohort study in Denmark
Authors' conclusion
Our analysis reveals compelling evidence of a reduced risk of amputation among patients receiving GLP-1 therapy, an effect dominated by liraglutide, compared to those without the treatment, even after adjusting for various socio-economic factors. However, further investigation is required to identify and account for any other potential confounding variables that may impact the outcome.
Study context
- Population
- Patients with T2D, Danish National Register and Diabetes Database
- Participants
- 309,116 patients
- Exposure
- GLP-1 agonist treatment vs no GLP-1 treatment
- Outcome
- Lower extremity amputation
Methodological detailsregistry-based, time-varying models
- Registry-based
- Time-varying models
Main finding
Amputation
Hazard ratio
0.5
95% CI 0.54–0.74
P < 0.005
As reported in the abstract
Observational data: associations, not effects.
Further findings
Amputation by age and income subgroups
- Risk reduction consistent across age groups; most pronounced among middle income patients
Amputation, time-varying Cox models accounting for comorbidity history
- Findings further validated by time-varying Cox models considering comorbidity history
Original publication
Glucagon-like peptide-1 treatment reduces the risk of diabetes-type 2 related amputations: A cohort study in Denmark. Diabetes Res Clin Pract. Published 28 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →